Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis (Q38259495)

1 September 2017

0 references

1 reference

title

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis (English)

1 reference

1 September 2017

0 references

1 reference

1 reference

1 reference

Raffaele Iorio

1

0 references

author name string

Valentina Damato

series ordinal

2

1 reference

1 September 2017

Paolo Emilio Alboini

series ordinal

3

1 reference

1 September 2017

Amelia Evoli

series ordinal

4

1 reference

1 September 2017

12 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

262

1 reference

1 September 2017

5

1 reference

1 September 2017

1115-1119

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-014-7532-3

1 September 2017

0 references

cites work

Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Guidelines for treatment of autoimmune neuromuscular transmission disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rituximab for myasthenia gravis: three case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Myasthenia gravis developing in a patient with CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Myocardial infarction after rituximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

B-cell therapies in established rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Long-lasting treatment effect of rituximab in MuSK myasthenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-014-7532-3

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

21 January 2018

1 reference

12 December 2020

CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

1 reference

12 December 2020

Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis

1 reference

12 December 2020

Rituximab in refractory MuSK antibody myasthenia gravis

1 reference

12 December 2020

The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy.

1 reference

12 December 2020

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series

1 reference

12 December 2020

Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

1 reference

12 December 2020

Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.

1 reference

12 December 2020

Rituximab for myasthenia gravis developing after bone marrow transplant

1 reference

12 December 2020

Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease

1 reference

12 December 2020

Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment

1 reference

12 December 2020

Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma

1 reference

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

10.1007/S00415-014-7532-3

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference